ADC Therapeutics S.A.

NYSE: ADCT · Real-Time Price · USD
3.17
-0.02 (-0.63%)
At close: Aug 15, 2025, 1:15 PM

ADC Therapeutics S.A. Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
69.28M 69.56M 209.91M 33.92M
Cost of Revenue
5.95M 2.53M 4.58M 1.39M
Gross Profit
63.33M 67.03M 205.33M 32.52M
Operating Income
-130.65M -165.99M -123.63M -261.72M
Interest Income
12.27M 10.54M 2.57M 66K
Pretax Income
-156.14M -195.42M -154.66M -251.5M
Net Income
-157.85M -240.05M -155.8M -230.03M
Selling & General & Admin
85.91M 105.89M 143.49M 136.24M
Research & Development
109.63M 127.13M 187.9M 158M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
192.27M 233.01M 328.96M 294.24M
Interest Expense
50.21M 46.33M 36.73M 18.34M
Selling & Marketing Expenses
21.44M 57.46M 35.75M 64.78M
Cost & Expenses
201.49M 235.54M 333.54M 295.64M
Income Tax Expense
166K 39.11M 1.14M -21.48M
Shares Outstanding (Basic)
97.16M 81.71M 78.15M 76.75M
Shares Outstanding (Diluted)
97.16M 81.71M 78.15M 76.75M
EPS (Basic)
-1.62 -2.94 -1.99 -3
EPS (Diluted)
-1.62 -2.94 -1.99 -3
EBITDA
-103.71M -146.76M -108.06M -223.72M
EBIT
-105.92M -150.03M -110.09M -233.16M
Depreciation & Amortization
3.28M 3.27M 2.39M 2.63M